Latest News about Vertex Pharmaceuticals Inc
Recent news which mentions Vertex Pharmaceuticals Inc
Cramer's Lightning Round: Vertex Pharmaceuticals is a buy
October 30, 2024
From CNBC.com News
Healthy Returns: Pfizer pulls sickle cell disease drug from markets – here’s why it matters
October 01, 2024
From CNBC.com News
Cramer's Lightning Round: Builders FirstSource 'can go higher'
August 28, 2024
From CNBC.com News
From CNBC.com News
New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle
February 23, 2024
From CNBC.com News
Vertex non-opioid painkiller shows positive results in critical late-stage trial on acute pain
January 30, 2024
From CNBC.com News
Vertex shares pop after non-opioid painkiller posts positive mid-stage trial results
December 13, 2023
From CNBC.com News
From CNBC.com News
U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients
December 07, 2023
From CNBC.com News
From CNBC.com News
From CNBC.com News
Cramer says Vertex has a drug that may address the 'largest market opportunity in the world'
October 09, 2023
From CNBC.com News
Cramer's Lightning Round: Vertex is 'excellent'
October 05, 2023
From CNBC.com News
Stocks making the biggest moves after hours: Arista Networks, MGM Resorts, Stryker and more
May 01, 2023
From CNBC.com News
Stocks making the biggest moves midday: Walgreens, Coinbase, Duolingo, Ralph Lauren and more
November 11, 2022
From CNBC.com News
Cramer's lightning round: Stay with Vertex Pharmaceuticals
October 27, 2022
From CNBC.com News
Stocks making the biggest moves after hours: Amazon, Apple, Pinterest, Intel and more
October 27, 2022
From CNBC.com News
From CNBC.com News
From CNBC.com News
Stocks making the biggest moves midday: Global Payments, Moderna, Activision Blizzard and more
May 02, 2022
From CNBC.com News
Some of the first quarter’s biggest losers could be the biggest steals, Jim Cramer says
April 04, 2022
From CNBC.com News
Stem cells may finally offer a cure for Type 1 diabetes
March 26, 2022
From CNBC.com News
Op-ed: Investors should look at technology, health care and industrials for long-term investing potential
March 23, 2022
Tickers
WAR
From CNBC.com News
The 30-year-old female founder at the forefront of a billion-dollar bet on CRISPR gene editing
March 12, 2022
From CNBC.com News
Cramer's lightning round: Oppenheimer Holdings is cheap and should rally with the financials
January 04, 2022
From CNBC.com News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
|
|
|